Selection of orlistat as a potential inhibitor for lipase from Candida species by Khedidja, Benarous & Abderrahman, Linani
open access  www.bioinformation.net  Hypothesis
  Volume 7(3) 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 7(3): 125-129 (2011)  125   © 2011 Biomedical Informatics
 
 
Selection of orlistat as a potential inhibitor for 
lipase from Candida species 
 
 
Benarous Khedidja1* & Linani Abderrahman2 
 
 
1Laboratoire des Sciences Fondamentales, Université Amar Telidji, Laghouat- Algérie; 2Biology department, Université 
Amar Telidji. Laghouat- Algérie; Benarous Khedidja – Email: benarouskh_1985@yahoo.fr; *Corresponding author 
 
 
Received August 29, 2011; Accepted August 30, 2011; Published September 28, 2011 
 
 
Abstract: 
Infections caused by Candida species manifest in a number of diseases, including candidemia, vulvovaginal candidiasis, 
endocarditis, and peritonitis. Candida species have been reported to possess lipolytic activity due to the secretion of lipolytic 
enzymes such as esterases, lipases and phospholipases. Extra-cellular hydrolytic enzymes seem to play an important role in 
Candida overgrowth. Candidiasis is commonly treated with antimycotics such as clotrimazole and nystatin. The 
antimycotics bind to a major component of the fungal cell membrane (ergosterol), forming pores that lead to death of the 
fungus. However, the secondary effects caused during such treatment have aroused a need to develop a treatment based on 
lipase inhibition. Nonetheless, no such lipase inhibitors for candidiasis treatment are currently available. Thus, we have 
performed a docking study with the natural inhibitor, orlistat or tetrahydrolipstatin. Our results have shown ten possible 
binding inhibitors to Candida rugosa lipase (CRL), out of which one possibility was selected, based on the weakest inter-
atomic distance of 2.7 Å. Therefore, we propose the selection and design of a potential inhibitor candidate, orlistat for the 
treatment of candidiasis infections. However, this study has to be supported with in vitro and in vivo experiments to 
demonstrate the effectiveness of orlistat in lipase inhibition. 
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Background: 
Candidiasis is the most common oral fungal infection 
caused by candida species in man and manifests in a variety 
of clinical guises ranging from pseudo-membranous 
(thrush), erythematous, and hyperplastic variants to more 
recently described linear gingival erythema associated with 
HIV infection [1]. Candida is ubiquitous and more than 200 
species have been described. Some species are part of our 
microbiological flora and only 10% are known to be 
responsible for infections in people [2]. The ARTEMIS 
Global Antifungal Surveillance Program showed that C. 
albicans was the most common (63–70%) candidal cause of 
invasive fungal infections, followed by C. glabrata (44%), 
Candida tropicalis (6%), and Candida parapsilosis (5%)  [3]. 
Candida rugosa has been rarely reported as a human 
pathogen. Recently, Colombo et al., (2003) have evaluated a 
cluster of Candida rugosa candidemia cases occurring in six 
hospitalized patients from a tertiary care teaching hospital 
in Sao Paulo, Brazil [4]. Polyene antibiotics nystatin (NYS) 
and amphotericin B (AmB) have been incessantly used in 
the treatment of topical (NYS) and systemic (AmB) fungal 
infections for more than 50 years now. The advantage of 
administering these compounds, which are more efficient 
and not replaceable with other agents belonging to different 
families of antifungal compounds, e.g. azoles, is their wide 
spectrum of activity towards pathogenic fungi and yeasts. 
However, their application is accompanied by serious side 
effects, resulting from compositional similarity between host 
and fungi cells [5]. Due to these secondary effects, other 
treatments based on the hydrolytic activity of extracellular 
secreted enzymes of fungi cells are needed [6]. An 
increasing amount of evidence associates lipases with 
microbial virulence. Putative roles of microbial extra-cellular 
lipases include the digestion of lipids for nutrient BIOINFORMATION  open access 
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acquisition, adhesion to host cells and host tissues, 
synergistic interactions with other enzymes, unspecific 
hydrolysis due to additional phospholipolytic activities, 
initiation of inflammatory processes by affecting immune 
cells and self-defense by lysing the competing microflora. 
The importance of extracellular secreted lipases has been 
demonstrated in C. albicans and C. parapsilosis. Additionally, 
Trofa  et al., (2009) have shown that disruption of lipases 
attenuates damage associated with C. albicans and C. 
parapsilosis murine infections. Hence, lipase has been 
identified as a possible target for the development of novel 
anti-fungal therapeutic compounds [7]. Orlistat or 
tetrahydrolipstatin is a competitive inhibitor of pancreatic 
lipase (PL) with β lactone cycle incorporated into a carbon 
skeleton. This molecule is an irreversible inhibitor of human 
pancreatic lipase with an IC50 value of 0.14 mM. The 
inhibitory activity of this molecule is lost when the β lactone 
ring is opened. It is currently used as approved anti-obesity 
drug  [8]. Although it is one of the best-selling drugs 
worldwide, it has certain unpleasant gastrointestinal side 
effects like oily stools, oily spotting, and flatulence among 
others [8].  
 
Lipases belong to the family of carboxylic ester hydrolases, 
also known as tri-acylglycerol hydrolases (EC.3.1.1.3). The 
physiological role of lipases is to hydrolyze triglycerides 
into diglycerides, monoglycerides, fatty acids and glycerol. 
Lipases also have the ability to perform synthetic reactions 
such as esterification (reaction between acid and alcohol), 
trans-esterification (ester and alcohol) and the inter-
esterification (ester and ester). Lipases have catalytic 
properties that vary according to species. The mechanism of 
lipase enzyme shows some similarities with the active serine 
proteases. Unlike other hydrolases, the active site of lipases 
is usually covered with a peptide loop formed by an 
amphiphilic α helix of about fifteen amino acids, that acts as 
flap (lid) [9-11]. When α helix covers the active site, the 
enzyme is in its closed or inactive conformation. In this 
conformation, the hydrophobic face of the amphiphilic helix 
interacts with hydrophobic residues surrounding the active 
site while its hydrophilic face interacts with water 
molecules. The substrate cannot be interacting with the 
catalytic triad. In the open or active conformation of the 
enzyme which is a result of interfacial activation 
mechanism, there is a shift of α helix constituting the cover. 
The hydrophobic face of the helix facing inward before the 
active site exposed to the solvent, creating a hydrophobic 
surface, assumed to interact with the interface water / fat. 
The active site of the enzyme is then accessible to the 
substrate.  
 
Based on the crystallographic data, some residues, different 
from the catalytic triad appear to be important in the 
catalytic mechanism. These residues form what is called the 
oxyanion hole. Their role is mainly to stabilize reaction 
intermediates, such as the tetrahedral intermediates. In the 
case of lipase from Candida rugosa, it is the nitrogen amide of 
Gly123 and Gly124 and Ala210 that appears to perform the 
same function [12]. The hydrolysis of a carboxylic ester by 
the catalytic triad can be divided into six main stages. First, 
the carbon of the carboxylic function of the substrate 
undergoes nucleophile attack of the hydroxyl group of 
serine whose nucleophilicity is enhanced by the histidine 
residue following the formation of a hydrogen bond. The 
imidazole ring of histidine becomes protonated and 
positively charged. This positive charge is stabilized by a 
charge of an acidic residue (Asp or Glu) (Figure 1(1)). This 
results in the formation of the first tetrahedral intermediate, 
stabilized by two hydrogen bonds with residues of the 
oxyanion hole (Figure 1(2)). Subsequently, there is release of 
a molecule of alcohol, formation of the acyl-enzyme (Figure 
1(3)) and nucleophile attack of the acyl-enzyme by a water 
molecule  (Figure 1(4)). This second nucleophile attack 
results in the formation of a second tetrahedral 
intermediate, stabilized by the oxyanion hole (Figure 1(5)).  
Finally, there is the fatty acid release and return of the 
enzyme in its original conformation (Figure 1(6)) [12-14]. 
Hence, we have studied the use of orlistat as another 
candidiasis treatment with low secondary effects.  
 
 
Figure  1: Schematic representation of the lipase ester-
cleavage reaction pathway: (1) non-covalent Michaelis 
complex; (2) first tetrahedral transition state; (3) formation 
of the acyl-enzyme and release of an alcohol molecule; (4) 
attack of a water molecule on the acyl-enzyme; (5) second 
tetrahedral transition state; (6) release of the fatty acid [12]. 
 
Methodology: 
Building the 3D structure of orlistat: 
The inhibitor model was built using Hyperchem software 
(www.hyper.com) based on Lewis structure. Atoms have 
been chosen from dialog box (default elements) in build 
menu. The 3D structure of the orlistat is shown in Figure 2. 
 
Optimizing the Structure of inhibitor model: 
In this step, the inhibitor model structure was minimized by 
performing a molecular mechanics optimization using MM+ 
force field and Polack Ribier algorithm to obtain the most 
stable structure geometry (Figure 1).  
 
Energetic calculations: 
A single point calculation was performed in order to 
compute the energy and gradient of the inhibitor model, this BIOINFORMATION  open access 
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method allowed the calculation of the total energy and 
gradient before the geometry optimization. 
 
 
Figure 2:  The 2D (a) and 3D (b) structure of orlistat. 
 
Enzyme structure optimization: 
The crystal structure coordinates of the lipases enzyme 
(1CRL for Candida rugosa lipase and PDB_ID: 1LPA for 
pancreatic human lipase) was obtained from the Protein 
Data Bank (PDB) (http://www.rcsb.org). Water molecules, 
hetero atoms and ligands such as sugars were removed [15]. 
All hydrogen atoms were added to the protein including 
those necessary to define the correct ionization and 
tautomeric states of amino acid residues using Hyperchem 
software. A two-step procedure was set up for the energy 
minimization of protein using the same software.  In the 
first step, all hydrogen atoms in the protein were allowed to 
optimize. The hydrogen locations are not specified by the X-
ray structure but these are necessary to improve the 
hydrogen bond geometries. In the second stage, all protein 
atoms were allowed to relax. Minimization in both stages 
was performed using 100 steps of steepest descent and 2000 
steps of conjugate gradient algorithm [16]. 
 
 
Figure 3: The binding modes of orlistat (shown as green 
lines) in the active site of both inter-atomic distances (shown 
as red dashes) represented in A: CRL, B: HPL, (2.7Å; 0.5 Å 
respectively). Triad catalytic shown with blue lines for both 
lipases. 
 
Docking procedure of orlistat: 
Docking of the inhibitor in the active site of the two lipases 
was carried out using GOLD 4.1.2 software (Genetic 
optimisation of ligand docking). The procedure consisted of 
three main parts: (1) A scoring function to rank different 
binding modes; the Gold score function is a molecular 
mechanics-like function with four terms, was used. (2) A 
mechanism for placing the ligand in the binding site; GOLD 
uses a unique method to do this, which is based on fitting 
point. (3) A search algorithm to explore possible binding 
modes; GOLD uses a genetic algorithm (GA) [17-18]. This 
method allows a partial flexibility of protein and full 
flexibility of ligand [19] for each of the 10 independent GA 
runs. 
 
Discussion: 
Prior to the docking, amino acids and the anatomy of the 
active site of both lipases (CRL and HPL) have been studied 
by consulting literature of previous works and also by using 
the software PyMOL to understand the specificity of the 
active site towards the substrate. The funnel-like binding 
pocket of HPL (13*4.5 Å at its base) consists of two hand 
walls. Its left-hand wall is the lowest of all lipase binding 
sites (4.5 Å). In addition, HPL is the only lipase where this 
left-hand wall is lower than both the left and the right-hand 
walls in the front view [20]. Similarly, the lid or the 
amphiphilic component of Cys 237 to Cys 261 [11] forms the 
left wall to the binding site of alcohol. The β 5-loop lies 
opposite to the lid and constitutes the right-hand wall of the 
alcohol binding site [20]. The binding pocket of CRL is 
exceptional and completely differs from those of the other 
lipases. Here, the scissile fatty acid binding site is located in 
a tunnel inside the protein with a wide entrance at the right-
hand side. This tunnel is at least 22 Å long with a diameter 
of about 4 Å. In the free CRL, this tunnel can hardly be 
predicted, since it is blocked by side chains. It is formed by 
G124 and A210 (oxyanion hole), F125, the catalytic S209, 
M213, V245, P246, F296, S301, L302, R303, L304, L307, F345, 
Y361, F362, S365, F366, V409, L410, L413, G414, F415, F532 
and V534 [20].  
 
The results of docking have shown 10 binding possibilities 
of orlistat in the active site of both lipases, and we have 
accepted one of them according to the weakest inter-atomic 
distance (ID) between the oxygen atom of the hydroxyl 
group of the catalytic amino acid Ser (for CRL: Ser209; for 
HPL: Ser152) and the ketone function of β lactone cycle of 
orlistat. It is attempted that this distance allows the 
formation of covalent bond between these described atoms 
basing on the catalytic mechanism. In docking, it is admitted 
that the affinity of the inhibitor towards lipase is related 
reciprocally with the ID value (when the ID value decreases 
the affinity increases). For CRL, we have recorded an ID of 
2.7 Å (Figure 3A) which is 5 times higher than the ID 
recorded for HPL, with a value of 0.5 Å (Figure 3B). From 
these results, it is attempted that orlistat presents a strong 
affinity to HPL than to CRL. The ID of experimental 
complexes of enzyme-inhibitor for both lipases has been 
calculated to compare the ID and the affinities of inhibitors 
to each lipase. An ID of 1.6 Å has been found between the 
phosphorus atom of (1S)-menthyl-hexyl-phosphonate 
(MHP) and the oxygen atom of Ser209 for CRL [21], this 
value is lower than the one found for orlistat which mean 
that this inhibitor presented a higher affinity (Table 1, see 
supplementary material). For HPL, an ID of 1.7 Å has been 
saved between the phosphorus atom of Methoxy-Undecyl-
Phosphinic acid (MUP) and the oxygen atom of Ser152 [22], 
when it is compared with this ID, it has been confirmed that 
orlistat is three times potent inhibitor than MUP (Table 1, 
see Supplementary material).   
 BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 7(3): 125-129  (2011)  128             © 2011 Biomedical Informatics
 
 
Conclusion:  
Docking studies of the natural competitive inhibitor 
(orlistat) in an attempt to discover a new candidiasis 
treatment is of interest. Orlistat has presented a higher 
affinity towards HPL than to CRL, and is also a more potent 
inhibitor than MUP for HPL, based on ID values of both 
lipases. These results have shown the potential of orlistat as 
a new candidate for candidiasis treatment with fewer side 
effects in comparison to nystatin. Nonetheless, experimental 
in vitro and in vivo studies are required to demonstrate the 
effectiveness of the inhibitor. Therefore, this study illustrates 
affinities of inhibitors to lipases which are considerably 
easier to implement, cheaper and faster compared to 
experimental methods.  
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Supplementary material: 
 
Table 1: The inter-atomic distance values of the complexes inhibitors - lipases 
Lipase Inhibitor 
Orlistat Methoxy-undecyl-phosphinic  acid  (1S)-menthyl-hexyl-phosphonate 
CRL 2.7  /  1.6 
HPL 0.5  1.7  / 
All values are in Å. 
 